Has Amelia Yeh received payments from drug or device companies?

Yes. Drug and device makers reported $94,952 in general payments to Amelia Yeh across 250 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amelia Yeh did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amelia Yeh come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amelia Yeh

Pulmonary Disease · Abilene, TXNPI 1023183928

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $82,600 of the $94,952 with a category attached, or 87.0%. GSK accounts for 96.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $53,545 and has fallen 66.4% since, to $17,987 in 2021. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$94,952in general payments, 2019–2025

Across 250 payments — averaging $379.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$92K
AstraZeneca$1K
Boehringer Ingelheim$932
Genentech USA, Inc.$184
United Therapeutics Corporation$183
Harmony Biosciences LLC$136
plus $584 from 12 others

What the payments were for

Consulting fees$4,8755%
Speaking & faculty fees$82,60087%
Travel & lodging$2,8073%
Food & beverage$4,4965%
Education$1740%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	147	$91,583
AstraZeneca	18	$1,351
Boehringer Ingelheim	40	$932
Genentech USA, Inc.	11	$184
United Therapeutics Corporation	5	$183
Harmony Biosciences LLC	5	$136
Mylan Specialty L.p.	3	$122
Pfizer	1	$103
Jazz Pharmaceuticals Inc.	4	$79
Sunovion Pharmaceuticals Inc.	4	$77
Grifols USA, LLC	2	$35
Takeda Pharmaceuticals U.S.A., Inc.	2	$32
Electromed, Inc.	2	$31
Philips North America LLC	2	$29
Chiesi USA, Inc.	1	$25
Inogen, Inc.	1	$21
Bayer	1	$17
Johnson & Johnson	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,952 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas →

Other pulmonary disease in Abilene

Antonio AnzuetoSan Antonio$1.8M
Diego Maselli CaceresSan Antonio$1.5M
Nicola HananiaHouston$1.3M
Juan IribarrenBeaumont$915K
William CalhounGalveston$568K
David MarksSan Antonio$453K
Sandeep SahayHouston$378K
Jefy MathewThe Woodlands$318K
Rodolfo Estrada AnzuetoSan Antonio$300K
Zeenat SafdarHouston$291K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →